Development of specific radiopharmaceuticals for infection imaging by targeting infectious micro-organisms

Current Pharmaceutical Design

Volumn 18, Issue 8, 2012, Pages 1098-1106

  Ferro Flores, Guillermina ^a   Ocampo Garcia, Blanca E ^a   Melendez Alafort, Laura ^b  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Antimicrobial peptides; Antiviral drugs; Radiolabeled antibiotics; Scintigraphy; Technetium 99m ubiquicidin

Indexed keywords

5 ETHYL 2' FLUOROURACIL ARABINOSIDE; ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA DEFENSIN 3; BETA LACTAM ANTIBIOTIC; CEFOPERAZONE; CEFTIZOXIME; CIPROFLOXACIN; ENVIROXIME; FIALURIDINE; FLUCONAZOLE; GALLIUM CITRATE GA 67; GANCICLOVIR; GLYCOPROTEIN GP 41; LACTOFERRIN; MALTOSE BINDING PROTEIN; NONSTRUCTURAL PROTEIN 3; OLIGOSACCHARIDE; POLYPEPTIDE ANTIBIOTIC AGENT; RADIOPHARMACEUTICAL AGENT; RNA POLYMERASE; SULFANILAMIDE; TECHNETIUM 99M; THYMIDINE KINASE; VIRUS DNA; VIRUS RNA;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CANDIDIASIS; CELL INFILTRATION; CELL LABELING; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DRUG EFFICACY; ENCEPHALITIS; ENZYME SPECIFICITY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; INFECTION; INFLAMMATION; ISOTOPE LABELING; LYMPH NODE METASTASIS; MEDIASTINITIS; MELANOMA; NONHUMAN; OSTEOMYELITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STAPHYLOCOCCUS INFECTION; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; MYCOSES; RADIOPHARMACEUTICALS; VIRUS DISEASES;

EID: 84857134772     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799315821     Document Type: Review

References (94)

1. Kok M, Pechere JC. Nature and pathogenicity of micro-organisms. In: Cohen J, Powderly WG eds. Infectious Diseases. St. Luis, MO: Mosby 2004:3-29.
2. Kowalsky RJ and Falen SW. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. American Pharmacy Association, 2nd ed. Washington DC, 2004.
3. Rennen HJ, Boerman OC, Oyen WJ. Imaging infection/inflammation in the new millennium. Eur J Nucl Med 2001; 28: 241-52.
4. Lin WY, Caho TH, Wang SJ. Clinical features and gallium scan in the detection of post-surgical infection in the elderly. Eur J Nucl Med Mol Imaging 2002; 29: 371-5.
5. Becker W, Palestro CJ, Winship J, et al. Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan). Clin Orthopaed Rel Res 1996; 263-72.
6. Welling M, Feitsma HIJ, Calame W, Pauwels EKJ. Detection of experimental infections with Tc-99m-labelled monoclonal antibodies against TNF-alpha and interleukin-8. Nucl Med Biol 1997; 24: 649-55.
7. Welling M, Feitsma HIJ, Calame W, Pauwels EKJ. Localization of a bacterial infection with Tc-99(m)-labelled human IgG: Further improvement with enriched IgG subclass preparations. Nucl Med Commun 1997; 18: 1057-64.
8. Rao PS, Pallela VR, Vassileva-Belnikolovska D, Jungkind D, Thakur ML. A receptor-specific peptide for imaging infection and inflammation. Nucl Med Commun 2000; 21: 1063-70.
9. Signore A, Chianelli M, Bei R, Oyen W, Modesti A. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine. Eur J Nucl Med Mol Imaging 2003; 30: 149-56.
10. Signore A, Mather SJ, Piaggo G, Malviya G, Dierckx RA. Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. Chem Rev 2010; 110: 3112-45.
11. Petruzzi N, Shanthly N, Thakur M. Recent trends in soft-tissue infection imaging. Semin Nucl Med 2008; 39: 115-23.
12. Chianelli M, Boerman OC, Malviya G, Galli F, Oyen WJG, Signore A. Receptor binding ligands to image infection. Curr Pharm Des 2008; 14: 3316-25.
13. Ujula T, Salomaki S, Virsu P, et al. Synthesis, 68Ga labelling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 2009; 36: 631-41.
14. Locke LW, Chordia MD, Zhang Y, et al. A novel neutrophilspecific PET imaging agent: cFLFLFK-PEG-64Cu. J Nucl Med 2009; 50: 790-7.
15. Brust D, Polis M, Davery R. Fluordeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006; 20: 985-93.
16. Kumar V. Radiolabelled white blood cells and direct targeting of microorganisms for infection imaging. Q J Nucl Med Mol Imaging 2005; 49: 325-38.
17. Welling M, Ferro-Flores G, Pirmettis I, Brouwer C. Current status of imaging infections with radiolabelled anti-infective agents. Anti- Infective Agents Med Chem 2009; 8: 272-87.
18. Bray M, Di Mascio M, de Kok-Mercado F, Mollura DJ, Jagoda E. Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes. Antiviral Res 2010; 88:129-42.
19. Brader P, Kelly K, Gang S, et al. Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One 2009; 4: e4789.
20. Kuruppu D, Brownell AL, Zhu A, et al. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res 2007; 67: 3295-300.
21. Diaz LA Jr, Foss CA, Thornton K, et al. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One 2007; 10: e1007.
22. Chakrabarti BK, Maitra RK, Ma XZ, Kestler HW. A candidate live inactivatable attenuated vaccine for AIDS. Proc Natl Acad Sci USA 1996; 93: 9810-15.
23. Green LA, Nguyen K, Berenji B, et al. A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J Nucl Med 2004; 45: 1560-70.
24. Miyagawa T, Gogiberidze G, Serganova I, et al. Imaging of HSVtk reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med 2008; 49: 637-48.
25. Serganova I, Ponomarev V, Blasberg R. Human reporter genes: potential use in clinical studies. Nucl Med Biol 2007; 34: 791-807.
26. Bennett JJ, Tjuvajev J, Johnson P, et al. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat Med 2001; 7: 859-63.
27. Alauddin MM, Conti PS, Mazza SM, Hamzeh FM, Lever JR. 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]- FHPG): a potential imaging agent of viral infection and gene therapy using PET. Nucl Med Biol 1996; 23: 787-92.
28. de Vries EF, van Waarde A, Harmsen MC, Mulder NH, Vaalburg W, Hospers GA. [11C]FMAU and [18F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nucl Med Biol 2000; 27: 113-9.
29. Buursma AR, de Vries EF, Garssen J, et al. [18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis. J Virol 2005; 79: 7721-7.
30. Lupetti A, De Boer MGJ, Erba P, Campa M, Nibbering PH. Radiotracers for fungal infection imaging. Med Mycology 2011; 49: S62-9.
31. Lupetti A, Welling M, Mazzi U, Nibbering PH, Pauwels EKJ. Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. Eur J Nucl Med Mol Imaging 2002; 29: 674-9.
32. Siaens R, Eijsink VG, Dierckx R, Slegers G. 123I-Labeled chitinase as specific radioligand for in vivo detection of fungal infection in mice. J Nucl Med 2004; 45: 1209-16.
33. Siaens R, Eijsink VG, Vaaje-Kolstad G, et al. Synthesis and evaluation of a 99mTechnetium labeled chitin-binding protein as potential specific radiligand for the detection of fungal infections in mice. Q J Nucl Med Mol Imaging 2006; 50: 155-66.
34. Shukla J, Arora G, Kotwal PP, Kumar R, Malhotra A, Bandopadhyaya GP. Radiolabeled oligosaccharides nanoprobes for infection imaging. Hell J Nucl Med 2010; 13: 218-23.
35. Gomes B, Rabiller G, Iglesias F, et al. 99mTc-ceftizoxime scintigraphy in normal rats and abscess induced rats. Rev Esp Med Nucl 2005; 24: 312-8.
36. Benitez A, Roca M, Martin-Comin J. Labeling of antibiotics for infection diagnosis. Q. J. Nucl Med Mol Imaging 2006; 50: 147-52.
37. Motaleb MA. Preparation of Tc-99m-cefoperazone complex, a novel agent for detecting sites of infection. J Radioanal Nucl Chem 2007; 272: 167-71.
38. Das SS, Hall AV, Wareham DW, Britton KE. Infection imaging with radiopharmaceuticals in the 21(st) century. Braz Arch Biol Technol 2002; 45: 25-37.
39. Muller M, Pena AD, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48: 1441-53.
40. Siaens RH, Rennen HJ, Boerman OC, Dierckx R, Slegers G. Synthesis and comparison of Tc-99m-enrofloxacin and Tc-99mciprofloxacin. J Nucl Med 2004; 45: 2088-94.
41. El Ghany EA, Amin AM, El Kawy OA, Amin M. Technetium-99m labeling and freeze-dried kit formulation of levofloxacin (L-Flox): A novel agent for detecting sites of infection. J Label Comp Radiopharm 2007; 50: 25-31.
42. Motaleb MA. Preparation and biodistribution of Tc-99mlomefloxacin and Tc-99m-ofloxacin complexes. J Radioanal Nucl Chem 2007; 272: 95-9.
43. Shah AQ, Khan MR. Radiosynthesis and biological evaluation of the 99mTc-tricarbonyl moxifloxacin dithiocarbamate complex as potential Staphylococcus aureus infection radiotracer. Appl Radiat Isot 2011; 69: 686-90.
44. Shah AQ, Khan AU, Khan MR. Radiosynthesis and biodistribution of 99mTc-rifampicin: a novel radiotracer for in vivo infection imaging. Appl Radiat Isot 2010; 68: 2255-60.
45. Oh SJ, Ryu JS, Shin JW, et al. Synthesis of 99mTc-ciprofloxacin by different methods and its biodistribution. Appl Radiat Isot 2002; 57: 193-200.
46. Rodriguez-Puig D, Piera C, Fuster D, et al. A new method of [Tc-99m]-ciprofloxacin preparation and quality control. J Label Comp Radiopharm 2006; 49: 1171-6.
47. Sarda L, Saleh-Mghir A, Peker C, Meulemans A, Cremieux AC, Le Guludec D. Evaluation of Tc-99m-ciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J Nucl Med 2002; 43: 239-45.
48. Dumarey N, Blocklet D, Appelboom T, Tant L, Schoutens A. Infecton is not specific for bacterial osteo-articular infective pathology. Eur J Nucl Med Mol Imaging 2002; 29: 530-5.
49. Sarda L, Cremieux AC, Lebellec Y, et al. Inability of Tc-99mciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J Nucl Med 2003; 44: 920-6.
50. Palestro CJ, Love C, Caprioli R, et al. Phase II study of 99mTcciprofloxacin uptake in patients with high suspicion of osteomyelitis [abstract]. J Nucl Med 2007; 47: 152.
51. Langer O, Brunner M, Zeitlinger M, et al. In vitro and in vivo evaluation of [F-18]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging 2005; 32: 143-50.
52. Zijlstra S, Gunawan J, Freytag C, Burchert W. Synthesis and evaluation of fluorine-18 labelled compounds for imaging of bacterial infections with PET. Appl Radiat Isot 2006; 64: 802-7.
53. Zhang J, Zhang S, Guo H, Wang X. Synthesis and biological evaluation of a novel 99mTc(CO)3 complex of ciprofloxacin dithiocarbamate as a potential agent to target infection. Bioorg Med Chem Lett 2010; 20: 3781-4.
54. Kyprianidou P, Tsoukalas C, Chiotellis A, et al. First example of well-characterized Re and 99mTc tricarbonyl complexes of ciprofloxacin and norfloxacin in the development of infection-specific imaging agents. Inorg Chim Acta 2011; 370: 236-42.
55. Zhang S, Zhang W, Wang Y, et al. Synthesis and biodistribution of a novel 99mTcN complex of norfloxacin dithiocarbamate as a potential agent for bacterial infection imaging. Bioconjug Chem 2011; 22: 369-75.
56. Roohi S, Mushtaq A, Jehangir M, Malik SA. Synthesis, quality control and biodistribution of Tc-99m-Kanamycin. J Radioanal Nucl Chem 2006; 267: 561-6.
57. Essouissi I, Ghali W, Saied NM, Saidi M. Synthesis and evaluation of 99mTc-N-sulfanilamide ferrocene carboxamide as bacterial infections detector. Nucl Med Biol 2010; 37: 821-9.
58. Hancock REW. Peptide antibiotics. Lancet 1997; 349: 418-22.
59. Mcphee JB, Hancock REW. Function and therapeutic potential of host defence peptides. J Pept Sci 2005; 11: 677-87.
60. Otvos, L. Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci 2005; 11: 697-706.
61. Ginsburg I. The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. Apmis 2002; 110: 753-70.
62. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
63. Welling M, Hiemstra PS, van den Barselaar MT, et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest 1998; 102: 1583-90.
64. Cole AM, Hong T, Boo LM, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. PNAS 2002; 99: 1813-8.
65. Lupetti A, Paulusma-Annema A, Welling M, Senesi S, Van Dissel JT, Nibbering PH. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother 2000; 44: 3257-63.
66. Nibbering PH, Welling M, Paulusma-Annema A, Brouwer CPJM, Lupetti A, Pauwels EKJ. Tc-99m-labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus. J Nucl Med 2004; 45: 321-6.
67. Sharma S, Verma I, Khuller GK. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 2001; 45: 639-40.
68. Brouwer CPJM, Bogaards SJP, Wulferink M, Velders MP, Welling M. Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multidrug resistant) Staphylococcus aureus in mice. Peptides 2006; 27: 2585-91.
69. Welling M, Paulusma-Annema A, Balter HS, Lanzzeri S, Souto B, Rey AM. Technetium-99m labeled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 2000; 27: 292-301.
70. Ferro-Flores G, Arteaga de Murphy C, Pedraza-Lopez M, et al. In vitro and in vivo assessment of 99mTc-UBI 29-41 specificity for bacteria. Nucl Med Biol 2003; 30: 597-603.
71. Melendez-Alafort L, Ramirez F, De M, et al. Arg and Lys in UBI: a specific site for a stable 99mTc complex?. Nucl Med Biol 2003; 30: 605-15.
72. Melendez-Alafort L, Rodriguez-Cortes J, Ferro-Flores G, et al. Biokinetics of 99mTc-UBI 29-41 in humans. Nucl Med Biol 2004; 31: 373-9.
73. Ferro-Flores G, Arteaga de Murphy C, Palomares-Rodriguez P, Melendez-Alafort L, Pedraza-Lopez M. Kit for instant 99mTc labelling of the antimicrobial peptide Ubiquicidin 29-41. J Radioanal Nucl Chem 2005; 266: 307-11.
74. Ferro-Flores G, Ramirez F De M, Melendez-Alafort L, Murphy CA, Pedraza-Lopez M. Molecular recognition and stability of 99mTc-UBI 29-41 based on experimental and semiempirical results. Appl Rad Isot 2004; 61: 1261-8.
75. Nibbering PH, Welling MM, Paulusma-Annema A, Brouwer CP, Lupetti A, Pauwels EK. 99mTc-labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus. J Nucl Med 2004; 45: 321-6.
76. Melendez-Alafort L, Nadali A, Pasut G, et al. Detection of sites of infection in mice using 99mTc-labeled PN2S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study. Nucl Med Biol 2009; 36: 57-64.
77. Gandomkar M, Najafi R, Shafiei M, et al. Clinical evaluation of antimicrobial peptide [99mTc/Tricine/HYNIC]-ubiquicidin 29-41 as a human-specific infection imaging agent. Nucl Med Biol 2009; 36: 199-205.
78. Akhtar MS, Iqbal J, Khan MA, Irfanullah J, Jehangir M, Khan B. 99mTc-labeled antimicrobial peptide ubiquicidin (29-41) accumulates less in Escherichia coli infection than in Staphlococcus aureus infection. J Nucl Med 2004; 45: 849-56.
79. Welling M, Lupetti A, Balter HS, Lanzzeri S, Souto B, Rey AM. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 2001; 42: 788-94.
80. Lupetti A, Pauwels EKJ, Nibbering PH, Welling MM. 99mTcantimicrobial peptides: promising candidates for infection imaging. Q J Nucl Med 2003; 47: 238-45.
81. Akhtar MS, Qaisar A, Irfanullah J, Iqbal J, Khan B, Jehangir M. Antimicrobial peptide 99mTc-Ubiquicidin 29-41 as human infection imaging agent: clinical trial. J Nucl Med 2005; 46: 567-73.
82. Lupetti A, Welling MM, Pauwels EKJ, Nibbering PH. Radiolabelled antimicrobial peptides for infection detection. Lancet Infect Dis 2003; 3:223-9.
83. Arteaga de Murphy C, Gemmel F, Balter J. Clinical trial of specific imaging of infections. Nucl Med Commun 2010; 31: 726-33.
84. Sepulveda-Mendez J, de Murphy CA, Rojas-Bautista JC, Pedraza- Lopez M. Specificity of 99mTc-UBI for detecting infection foci in patients with fever in study. Nucl Med Commun 2010; 31:889-95.
85. Dillmann-Arroyo C, Cantu-Leal R, Campa-Nunez H, et al. Application of the ubiquicidin 29-41 scan in the diagnosis of pyogenic vertebral osteomyelitis. Acta Ortop Mex 2011; 25: 27-31.
86. Vallejo E, Martinez I, Tejero A, et al. Clinical utility of 99mTclabeled ubiquicidin 29-41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch Med Res 2008; 39: 768-74.
87. Assadi M, Vahdat K, Nabipour I, et al. Diagnostic value of 99mTcubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging. Nucl Med Commun 2011; 32:716-23.
88. Nazari B, Azizmohammadi Z, Rajaei M, et al. Role of 99mTcubiquicidin 29-41 scintigraphy to monitor antibiotic therapy in patients with orthopedic infection: a preliminary study. Nucl Med Commun 2011; 32: 745-51.
89. Nibbering PH, Ravensbergen E, Welling M, et al. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 2001; 69: 1469-76.
90. Welling M, Brouwer CPJM, Hof W, Veerman ECI, Amerongen AN. Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards Multidrug-Resistant Staphylococcus aureus in vivo. Antimicrob Agents Chemother 2007; 51: 3416-9.
91. van Berkel PHC, Welling M, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol 2002; 20: 484-7.
92. Liberatore M, Pala A, Scaccianoce S, et al. Microbial targeting of 99mTc-labeled recombinant human beta-defensin-3 in an animal model of infection: a feasibility pilot study. J Nucl Med 2009; 50:823-6.
93. Ferro-Flores G., de Murphy CA. Current developments in SPECT/CT systems using 99mTc-radiopharmaceuticals. Rev Invest Clin 2007; 59: 373-81.
94. ÓConnor MK, Kemp BJ. Single-photon emission computed tomography/ computed tomography: basic instrumentation and innovations. Semin Nucl Med 2006; 36: 258-66.